Anlon Healthcare IPO is a book-built issue, aiming to raise ₹121.03 crore. The IPO comprises a fresh issue of 1.33 crore equity shares aggregating to ₹121.03 crore. The bidding window was open from August 26, 2025, to August 29, 2025, with the IPO allotment to be finalised on September 1, 2025. Anlon Healthcare is scheduled to list on BSE and NSE on September 3, 2025.
The IPO was priced at ₹86–₹91 per share with a lot size of 164 shares. The public issue received bids for 9,47,08,360 shares against 1,33,00,000 shares available, resulting in an overall subscription of 7.12 times. Retail investors subscribed 47.26 times, NIIs subscribed 10.61 times, while QIBs subscribed 1.07 times.
Anlon Healthcare’s ₹121.03 crore IPO, priced at ₹86–₹91 per share, was subscribed 7.12 times overall. The IPO consists entirely of a fresh issue of 1.33 crore equity shares aggregating to ₹121.03 crore. Bidding took place from August 26 to August 29, 2025, with the Anlon Healthcare IPO allotment status on September 1, 2025. Retail investors subscribed 47.26 times, NIIs 10.61 times, and QIBs 1.07 times. Listing is expected on September 3, 2025.
The table below breaks down the Anlon Healthcare share allocation for different categories, highlighting the number of shares and their percentage of the total issue. However, the key focus remains on the quotas allocated to retail investors and HNIs, as they are the most relevant for individual investors.
| Investor Category | Shares Offered |
| QIB Shares Offered | 9,975,000 |
| − QIB (Ex. Anchor) Shares Offered | 9,975,000 |
| NII (HNI) Shares Offered | 19,95,000 (15.00%) |
| − bNII > ₹10L | 13,30,000 (10.00%) |
| − sNII < ₹10L | 6,65,000 (5.00%) |
| Retail Shares Offered | 13,30,000 (10.00%) |
| Total Shares Offered | 1,33,00,000 (100.00%) |
Data Source: NSE
| Category | Subscription (times) |
| Qualified Institutional Buyers | 1.07 |
| Non-Institutional Investors | 10.61 |
| Retail Individual Investors | 47.26 |
| Total | 7.12 |
Note: The subscription details are as of August 29, 2025
Anlon Healthcare Limited was incorporated in 2013 and operates as a pharmaceutical manufacturing company. The firm specialises in producing high-purity pharmaceutical intermediates and active pharmaceutical ingredients (APIs). These products are key inputs used in the formulation of medicines, nutraceuticals, personal care items, and veterinary products. The company follows stringent standards such as IP, BP, EP, JP, and USP to ensure compliance with both Indian and international pharmacopeia.
The company’s product portfolio is diverse, consisting of sixty-five commercialised products, twenty-eight products at the pilot stage, and forty-nine products under laboratory testing. Its intermediates include Cyanoethylbenzoic acid, Ketonitrile, and Methyldesloratadine, which serve as starting materials or advanced intermediates for APIs. In addition, the company manufactures APIs like loxoprofen sodium dihydrate and loxoprofen acid, which have received approvals from regulatory agencies such as ANVISA, NMPA, and PMDA.
To support its operations, Anlon Healthcare has filed twenty-one Drug Master Files (DMFs) with global authorities and continues to work on approvals for Ketoprofen and Dexketoprofen Trometamol. The firm also provides custom manufacturing for complex chemicals, offering high levels of purity and low impurity content to meet the specific requirements of its clients. This flexibility enables it to build strong partnerships with both domestic and international customers.
The company maintains high standards of quality through rigorous testing, analysis, and process improvements. It is supported by four dedicated laboratories and a workforce of thirty-four members, of which twenty-four are science graduates. By combining strong research capabilities with experienced promoters and an emphasis on safety, quality, and compliance, Anlon Healthcare has created a competitive position within the pharmaceutical supply chain.
Know more about IPO allotment status and check your application details online for the latest updates on share allocation.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Aug 29, 2025, 9:12 PM IST
Akshay Shivalkar
Akshay Shivalkar is a financial content specialist who strategises and creates SEO-optimised content on the stock market, mutual funds, and other investment products. With experience in fintech and mutual funds, he simplifies complex financial concepts to help investors make informed decisions through his writing.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
